Tempus AI Inc. Class A Common Stock (TEM)
Stock · NASDAQ · Technology
$64.7as of 10/16/2026
Price chart
Active signals
TEM Signal Track Record
How signals performed across all stocks →What TEM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 8 | +3.0% | 50% | September 17, 2026 |
| Volume Spike | 7 | +7.7% | 57% | October 6, 2026 |
| Bollinger Band Breakdown | 7 | +8.8% | 86% | July 22, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +10.0% | 75% | January 8, 2026 |
| Any 20-session window (baseline) | +3.9% | 55% |
Computed by MarketWall from daily closing prices since April 2, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TEM
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an…
- Sector
- Technology
- Industry
- Computer Software: Programming Data Processing
- Employees
- 3,800
- Website
- investors.tempus.com/
Fundamentals
- 1-day range
- $63.79$72.5
- Market cap
- $8.32B
- P/E (trailing)
- —
- P/E (forward)
- -1373.81
- EPS (trailing)
- $-1.43
- Dividend yield
- —
- Beta
- 2.37
- Avg. volume
- 6.96M
How Tempus AI Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
18 analyst ratings
Tempus AI Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- TEMTempus AI Inc. Class A Common Stock$64.72▼ 9.01%Market cap $8.32BP/E —$40.77$97.25
- TTDThe Trade Desk Inc. Class A Common Stock$12.23▼ 6.85%Market cap $8.31BP/E 15.17$11.62$55.11
- MTCHMatch Group Inc. Common Stock$42.95▼ 2.61%Market cap $8.54BP/E 14.15$28.81$44.94
- SNAPSnap Inc. Class A Common Stock$6.13▼ 4.81%Market cap $8.83BP/E —$3.81$9.13
- BZKANZHUN LIMITED American Depository Shares$16.74▲ 2.26%Market cap $7.45BP/E 11.10$12.57$22.81
- FDSFactSet Research Systems Inc. Common Stock$301.67▼ 0.05%Market cap $9.77BP/E 19.49$185$320.48
- GDSGDS Holdings Limited ADS$23.08▼ 8.85%Market cap $6.38BP/E 10.34$24.02$46.94
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TEM Tempus AI Inc. Class A Common Stock | $8.32B | — | $64.72 | ▼ 9.01% | $40.77$97.25 |
| TTD The Trade Desk Inc. Class A Common Stock | $8.31B | 15.17 | $12.23 | ▼ 6.85% | $11.62$55.11 |
| MTCH Match Group Inc. Common Stock | $8.54B | 14.15 | $42.95 | ▼ 2.61% | $28.81$44.94 |
| SNAP Snap Inc. Class A Common Stock | $8.83B | — | $6.13 | ▼ 4.81% | $3.81$9.13 |
| BZ KANZHUN LIMITED American Depository Shares | $7.45B | 11.10 | $16.74 | ▲ 2.26% | $12.57$22.81 |
| FDS FactSet Research Systems Inc. Common Stock | $9.77B | 19.49 | $301.67 | ▼ 0.05% | $185$320.48 |
| GDS GDS Holdings Limited ADS | $6.38B | 10.34 | $23.08 | ▼ 8.85% | $24.02$46.94 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Canaccord Genuity Maintains Buy on Tempus AI, Raises Price Target to $95benzinga · 10/12/2026
- Could You Have Seen The Run In Tempus AI Stock Coming?Yahoo · 10/9/2026
- Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?Yahoo · 10/9/2026
- Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine InfrastructureBenzinga · 10/7/2026
- Tempus Announces Multi-Year Collaboration with Moderna and MerckYahoo · 10/7/2026
- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeekingAlpha · 10/7/2026
- Dow Jones Futures Fall, Yields Rise After S&P 500 Hits High; Astera, GE Vernova, Arista Lead BuysYahoo · 10/7/2026
- The FDA Has Accepted And Granted Priority Review To The Biologics License Application For Daiichi Sankyo/Merck's Patritumab Deruxtecan For Pretreated Locally Advanced Or Metastatic EGFR-Mutated Non-small Cell Lung CancerBenzinga · 10/7/2026
- Dow Jones Futures: S&P 500 Hits High As Astera, GE Vernova, Arista Lead Buys, But These Stocks TumbleYahoo · 10/7/2026
Insider Activity
Insider Actions →- Thomas Edward Schoenherr · September 25, 2026 · Sale10.3K @ $85
- Eric P. Lefkofsky · September 22, 2026 · Sale79.3K @ $77.29
- Eric P. Lefkofsky · September 22, 2026 · Sale17.4K @ $76.57
- Eric P. Lefkofsky · September 22, 2026 · Sale184 @ $78.86
- Eric P. Lefkofsky · September 22, 2026 · Sale16.2K @ $78.23
- Eric P. Lefkofsky · September 22, 2026 · Sale33.8K @ $77.29
- Eric P. Lefkofsky · September 22, 2026 · Sale7.4K @ $76.57
- Eric P. Lefkofsky · September 22, 2026 · Sale160 @ $78.86
- Eric P. Lefkofsky · September 22, 2026 · Sale14.0K @ $78.23
- Eric P. Lefkofsky · September 22, 2026 · Sale29.4K @ $77.29
- Eric P. Lefkofsky · September 22, 2026 · Sale6.4K @ $76.57
- Eric P. Lefkofsky · September 22, 2026 · Sale24 @ $78.86
- Eric P. Lefkofsky · September 22, 2026 · Sale2.1K @ $78.23
- Eric P. Lefkofsky · September 22, 2026 · Sale4.4K @ $77.29
- Eric P. Lefkofsky · September 22, 2026 · Sale965 @ $76.57
Institutional Ownership
March 31, 2026
- Total shares held
- 115.63M
- Total value held
- $5.19B
- Institutional holders
- 421
- Unknown9.61M
- Unknown8.97M
- Unknown8.65M
- Unknown6.87M
- Unknown6.61M
- Unknown5.41M
- Unknown5.33M
- Unknown4.92M
- Unknown4.33M
- Unknown4.33M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tempus AI Expands Collaborations, Canaccord Raises Target to $95
Tempus AI is expanding its strategic collaborations to support future growth. Canaccord Genuity recently raised its price target for the stock to $95. This development occurs as the company prepares to report its third-quarter financial results on November 2.
Tempus AI Expands Collaborations, Canaccord Raises Target to $95. Tempus AI is expanding its strategic collaborations to support future growth. Canaccord Genuity recently raised its price target for the stock to $95. This development occurs as the company prepares to report its third-quarter financial results on November 2.